The targeted therapy has shown positive results in a clinical trial evaluating progression-free survival for lung cancer patients.
Enhertu, a targeted cancer therapy, has demonstrated a progression-free survival benefit in a clinical trial involving lung cancer patients.
Further details regarding the trial data, specific patient cohorts, and statistical significance were not immediately available in the initial announcement.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →